Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has developed and validated ...
Brazilian Health Regulatory Agency (ANVISA) has granted approval for Telix Pharmaceuticals’ Illuccix, a prostate cancer imaging agent. Illuccix claims to be the first prostate-specific membrane ...
Stockhead on MSN15h
Health Check: Fantastico! Telix wins Brazilian assent for prostate cancer imaging agentBrazil's health regulators have approved Telix Pharmaceuticals' nuclear imaging agent for prostate cancer, Illucix.
It’s a brave call given the recent market sell-off, but the ASX’s ‘milestone’ moment represents a structural change.
MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the Brazilian Health ...
In a report released today, Shane Storey from Wilsons maintained a Buy rating on Telix Pharmaceuticals Ltd. (TLPPF – Research Report), with a ...
(MENAFN- GlobeNewsWire - Nasdaq) MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces ...
MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, ...
MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX , Telix, the Company) today announces that it has developed and validated ...
TLX opened at $17.30 on Friday. The firm’s fifty day simple moving average is $17.47. Telix Pharmaceuticals Limited American Depositary Shares has a 52-week low of $14.01 and a 52-week high of $30.36.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback